Managing diabetes: what to do about cardiovascular disease

被引：6

作者：

Adler, AI ^{[1
]}

机构：

[1] Oxford Ctr Diabet & Metab, Diabet Trials Unit, Oxford OX3, England

来源：

DIABETES RESEARCH AND CLINICAL PRACTICE | 2003年 / 61卷

关键词：

atherosclerosis; coronary heart disease; dyslipidaemia; hyperglycaemia; statins;

D O I：

10.1016/S0168-8227(03)00127-X

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Type 2 diabetes increases the risk of coronary heart disease (CHD) 2-4-fold, making CHD the predominant cause of death in patients with diabetes. Currently identified risk factors include, among others, hyperglycaemia, hypertension and dyslipidaemia. Since studies show that intensive glycaemic control alone will not overcome the excess CHD risk, reducing blood pressure by any means and lipid levels by using statins and fibrates is effective in reducing CHD and associated mortality in patients with type 2 diabetes. Other interventions include aspirin therapy and the use of angiotensin-converting enzyme (ACE) inhibitors. (C) 2003 Published by Elsevier Ireland Ltd.

引用

页码：S3 / S8

页数：6

共 29 条

[1] Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64) [J].

Adler, AI ;

Stevens, RJ ;

Manley, SE ;

Bilous, RW ;

Cull, CA ;

Holman, RR .

KIDNEY INTERNATIONAL, 2003, 63 (01) :225-232

[2] UKPDS 59: Hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes [J].

Adler, AI ;

Stevens, RJ ;

Neil, A ;

Stratton, IM ;

Boulton, AJM ;

Holman, RR .

DIABETES CARE, 2002, 25 (05) :894-899

[3] Cardiovascular risk reduction in diabetes: underemphasised and overdue. Messages from major trials [J].

Adler, AI .

CLINICAL MEDICINE, 2001, 1 (06) :472-477

[4]

*AM DIAB ASS, 2001, DIABETES CARE S1, V24, pS58

[5]

[Anonymous], 2000, Lancet, V355, P253, DOI DOI 10.1016/S0140-6736(99)12323-7

[6] Diabetes and atherosclerosis - Epidemiology, pathophysiology, and management [J].

Beckman, JA ;

Creager, MA ;

Libby, P .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (19) :2570-2581

[7] Aspirin for the primary prevention of cardiovascular events: Recommendation and rationale [J].

Berg, AO ;

Allan, JD ;

Frame, PS ;

Homer, CJ ;

Johnson, MS ;

Klein, JD ;

Lieu, TA ;

Mulrow, CD ;

Orleans, CT ;

Peipert, JF ;

Pender, NJ ;

Siu, AL ;

Teutsch, SM ;

Westhoff, C ;

Woolf, SH .

ANNALS OF INTERNAL MEDICINE, 2002, 136 (02) :157-160

[8] Acarbose for prevention of type 2 diabetes mellitus: the STOPNIDDM randomised trial [J].

Chiasson, JL ;

Josse, RG ;

Gomis, R ;

Hanefeld, M ;

Karasik, A ;

Laakso, M .

LANCET, 2002, 359 (9323) :2072-2077

[9] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].

Cleeman, JI ;

Grundy, SM ;

Becker, D ;

Clark, LT ;

Cooper, RS ;

Denke, MA ;

Howard, WJ ;

Hunninghake, DB ;

Illingworth, DR ;

Luepker, RV ;

McBride, P ;

McKenney, JM ;

Pasternak, RC ;

Stone, NJ ;

Van Horn, L ;

Brewer, HB ;

Ernst, ND ;

Gordon, D ;

Levy, D ;

Rifkind, B ;

Rossouw, JE ;

Savage, P ;

Haffner, SM ;

Orloff, DG ;

Proschan, MA ;

Schwartz, JS ;

Sempos, CT ;

Shero, ST ;

Murray, EZ .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497

[10]

Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3

← 1 2 3 →